SCHEMBL3634572

SCHEMBL3634572

CCCC(=O)c1ccc(NCc2ccc(OC)nc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.51
NAMPT P43490 1/20 0.45
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
MLLT1 Q03111 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
FRK P42685 1/20 0.43
CAMK2B Q13554 1/20 0.43
CAMK2G Q13555 1/20 0.43
CAMK2D Q13557 1/20 0.43
ADORA2A P29274 1/20 0.43
NNMT P40261 1/20 0.43
NPC1 O15118 2/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3639356 0.83 ACACB (0.45) HDAC1FRKCAMK2BCAMK2GCAMK2D
SCHEMBL3636770 0.82 FRK (0.47) HDAC1CA1CA2MEN1KMT2A
SCHEMBL3637302 0.82 MAPT (0.50) HDAC1NAMPTMEN1KMT2AKDM4E
SCHEMBL3635601 0.81 L3MBTL1 (0.44) HDAC1NAMPTCA1CA2MAPT
SCHEMBL3635242 0.80 FRK (0.54) HDAC1NAMPTFRKCAMK2BCAMK2G
SCHEMBL3638402 0.79 SMN1; SMN2 (0.51) HDAC1CA1CA2MEN1KMT2A
SCHEMBL3640510 0.77 FRK (0.44) HDAC1CA1CA2MAPTFRK
SCHEMBL3637884 0.77 DDR1 (0.46) HDAC1CA1CA2MAPTFRK
SCHEMBL19002492 0.77 MLLT1 (0.51) NAMPTMLLT1MEN1KMT2AKDM4E
SCHEMBL3634267 0.76 ALDH1A1 (0.59) HDAC1NAMPTMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 HDAC1 658/4885NAMPT 2546/4885CA1 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.